Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction to: GMMA Technology for the Development of Safe Vaccines: Meta-Analysis of Individual Patient Data to Assess the Safety Profile of Shigella sonnei 1790GAHB Vaccine in Healthy Adults, with Special Focus on Neutropenia.
De Ryck I, Sarakinou E, Nakakana U, Cilio GL, Ndiaye A, Vella V, Auerbach J, Granada JP, Conti V, Podda A. De Ryck I, et al. Among authors: nakakana u. Infect Dis Ther. 2022 Jun;11(3):1313. doi: 10.1007/s40121-022-00634-8. Infect Dis Ther. 2022. PMID: 35435576 Free PMC article. No abstract available.
GMMA Technology for the Development of Safe Vaccines: Meta-Analysis of Individual Patient Data to Assess the Safety Profile of Shigella sonnei 1790GAHB Vaccine in Healthy Adults, with Special Focus on Neutropenia.
De Ryck I, Sarakinou E, Nakakana U, Cilio GL, Ndiaye A, Vella V, Auerbach J, Granada JP, Conti V, Podda A. De Ryck I, et al. Among authors: nakakana u. Infect Dis Ther. 2022 Apr;11(2):757-770. doi: 10.1007/s40121-022-00596-x. Epub 2022 Feb 3. Infect Dis Ther. 2022. PMID: 35118580 Free PMC article.
Complement-mediated serum bactericidal activity of antibodies elicited by the Shigella sonnei GMMA vaccine in adults from a shigellosis-endemic country: Exploratory analysis of a Phase 2a randomized study.
Kapulu MC, Nakakana U, Sciré AS, Sarakinou E, Conti V, Rossi O, Acquaviva A, Necchi F, Obiero CW, Martin LB, Bejon P, Njuguna P, Micoli F, Podda A. Kapulu MC, et al. Among authors: nakakana u. Front Immunol. 2022 Sep 9;13:971866. doi: 10.3389/fimmu.2022.971866. eCollection 2022. Front Immunol. 2022. PMID: 36203568 Free PMC article. Clinical Trial.
Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension.
Micoli F, Rossi O, Conti V, Launay O, Sciré AS, Aruta MG, Nakakana UN, Marchetti E, Rappuoli R, Saul A, Martin LB, Necchi F, Podda A. Micoli F, et al. Front Immunol. 2021 May 4;12:671325. doi: 10.3389/fimmu.2021.671325. eCollection 2021. Front Immunol. 2021. PMID: 34017343 Free PMC article. Clinical Trial.
Towards a Four-Component GMMA-Based Vaccine against Shigella.
Micoli F, Nakakana UN, Berlanda Scorza F. Micoli F, et al. Among authors: nakakana un. Vaccines (Basel). 2022 Feb 18;10(2):328. doi: 10.3390/vaccines10020328. Vaccines (Basel). 2022. PMID: 35214786 Free PMC article. Review.
Putative correlates of protection against shigellosis assessing immunomarkers across responses to S. sonnei investigational vaccine.
Conti V, Rossi O, Clarkson KA, Mancini F, Nakakana UN, Sarakinou E, Callegaro A, Ferruzzi P, Acquaviva A, Arora AK, Marchetti E, Necchi F, Frenck RW Jr, Martin LB, Kaminski RW, Podda A, Micoli F. Conti V, et al. Among authors: nakakana un. NPJ Vaccines. 2024 Mar 8;9(1):56. doi: 10.1038/s41541-024-00822-2. NPJ Vaccines. 2024. PMID: 38459072 Free PMC article.
14 results